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Dysregulation of microRNA networks has been implicated in hematological malignancies. One of the reasons for
disturbed miRNA-mediated regulation are polymorphisms in miRNA-binding sites (miRSNPs), which alter the
strength of miRNA interaction with target transcripts. In the recent years the first findings of miRSNPs associated
with risk and prognosis in hematological malignancies have been reported. From the studies described in this
review miRSNPs not only emerge as novel markers of risk and prognosis but can also lead to better understanding
of the role of miRNAs in regulating gene expression in health and disease.
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The non-protein coding parts of the genome have been
recognized as key players in the regulation of gene expres-
sion. Among various classes of non-coding RNAs, the best
known are microRNAs (miRNA), small (~22 nucleotide)
RNA molecules. MiRNAs bind to complementary target
sequences usually located in the 3’ untranslated region
(3’UTR) of mRNAs and act predominantly by negatively
regulating gene expression [1]. According to the miRBase
database, a catalog of miRNA sequences in animals, plants
and viruses, so far over 2500 mature human miRNAs have
been characterized [2]. Since miRNAs are predicted to
regulate over 60% of human protein-coding genes [3], it is
not surprising that they have been shown to regulate a
plethora of biological processes, including cell proliferation,
apoptosis, differentiation and metabolism [4]. Several lines
of evidence have demonstrated that miRNAs are required
for normal hematopoiesis, while miRNA dysregulation has
been associated with the pathogenesis of hematological
malignancies [5,6].
The crucial step in the process of miRNA-mediated regu-
lation of gene expression is recognition of the target tran-
script by miRNA. In animals this recognition is based on
pairing of the nucleotides 2-7 of miRNA (so called ‘seed’ re-
gion) with complementary sequences in the mRNA, which
are usually located in the 3’UTR, but can also be present inCorrespondence: krawczyk@man.poznan.pl
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article, unless otherwise stated.the 5’UTR or in the coding region. In addition, pairing of
nucleotides 13-16 of the miRNA enhances the miRNA-
mRNA interaction and the efficiency of miRNA binding
depends also on target site accessibility and secondary
structure of the miRNA-target duplex [7]. The requirement
for a strict Watson-Crick pairing between the ‘seed’ region
of miRNA and its target transcript implies that genetic
variability in the 3’UTR can affect miRNA binding by
destroying existing sites or creating new miRNA-mRNA
interactions. Computational analysis identified hundreds of
single nucleotide polymorphisms (SNPs) located within
predicted and experimentally verified miRNA-binding sites
or potentially creating novel sites for miRNA binding.
Moreover, there is evidence for a strong negative selection
on SNPs in miRNA-binding sites (miRSNPs) as compared
to the entire 3’UTR sequence [8-10], which supports the
functional significance of those sites. In the recent years
several studies have shown association of miRSNPs with
cancer and other diseases [11,12]. In the field of hema-
tological malignancies the first evidence for a disease-
associated miRSNP came in 2012 [13] and since then six
other studies have been published. Here I will systematic-
ally review the so far presented evidence for the relevance
of miRSNPs for leukemias, lymphomas and myeloma.KRT81 and XPO5 in lymphomas and myeloma
The prognostic value of six SNPs located in either genes
encoding proteins involved in the miRNA biogenesis or in
miRNA-binding sites located in myeloma-related genesCentral Ltd. This is an Open Access article distributed under the terms of the
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underwent autologous stem cell transplantation [13]. Asso-
ciation with survival was observed for two SNPs: CC geno-
type of rs3660 in KRT81 conferred longer overall survival
(OS), while patients with CC/AC genotype of rs11077 in
XPO5 had significantly longer OS and progression-free sur-
vival (PFS) (Table 1). KRT81 belongs to a family of hair ker-
atins which are involved in maintaining cell integrity and
regulating cell motility and growth in epithelial cells, and
have been described as prognostic markers in epithelial tu-
mors [14]. The C allele of rs3660 in KRT81 reduced signifi-
cantly the protein level in luciferase reporter assay in one of
two myeloma cell lines (RPMI-8226). Also in healthy lym-
phocytes a significant reduction of KRT81 protein, but not
mRNA, level was observed. Furthermore, a significant
decrease of the proliferation rate of RPMI-8226 cells was
observed upon silencing of the KRT81 gene, which indi-
cates the possible mechanism underlying the better prog-
nosis in myeloma patients carrying the CC genotype of
KRT81_rs3660. However, although the authors indicate that
according to bioinformatics prediction the C allele destroys
binding sites for several miRNAs, results of their experi-
ments indicate otherwise – that in myeloma cell lines and
healthy lymphocytes this SNP enhances binding of some
miRNAs, which results in decreased protein levels. Since
levels of specific miRNAs were not controlled in the lucifer-
ase assay, it is not clear whether the observed effect is a
consequence of altered miRNA binding, and if so – of
which specific miRNA. rs3660 in KRT81 was also studied
in Hodgkin lymphoma (HL) [15]. Here, the GG genotype
was found more frequently in patients (30.9%) than in the
European population (18.3%, data from the HapMap pro-
ject) but this should be validated in a control group ethnic-
ally matched with patients. Further analysis showed that
although rs3660 had no influence on survival of HL pa-
tients, the GG genotype is an independent risk factor for
treatment-related neurological toxicity. In non-Hodgkin
lymphoma (NHL), in turn, distribution of rs3660 genotypes
did not differ between patients and control group but car-
riers of CC and CG genotypes had significantly longer OS
compared to the GG genotype [16]. The studies in lymph-
omas did not attempt to verify whether rs3660 in KRT81
affects miRNA binding and what are the functional conse-
quences of the polymorphism.
The second polymorphism found to affect survival of
patients with multiple myeloma was rs11077 in XPO5.
This miRSNP, apart from its potential impact on expres-
sion of XPO5, can also affect the whole miRNA-ome of
the cell as XPO5 encodes for exportin-5, which is required
for the export of precursor miRNAs from nucleus to cyto-
plasm where they are subject to further steps of matur-
ation [17]. Bioinformatics analysis indicated that the C
allele of XPO5_rs11077 creates a new binding site for
miR-4763-5p. Indeed, luciferase reporter assay showed asignificant reduction in protein levels in two myeloma cell
lines. Also, in healthy lymphocytes the CC genotype was
associated with slightly decreased XPO5 protein levels,
but the difference did not reach statistical significance
[13]. However, it remains to be established whether miR-
4763-5p or another miRNA is responsible for the observed
effect. Also, the mechanism by which reduced XPO5 levels
could contribute to a better prognosis in multiple mye-
loma needs to be elucidated. rs11077 in XPO5 was also
studied in Hodgkin lymphoma [15]. Here, the AC geno-
type was associated with longer overall and disease-free
survival (DFS), as well as with lower rate of bleomycin-
associated pulmonary toxicity. Better performance of het-
erozygous patients seems somewhat unusual and probably
a replication in a larger cohort of patients could indicate
which allele is associated with a better prognosis. This
study did not provide any further clues for the functional
significance of XPO5_rs11077.
TP53 and diffuse large B-cell lymphoma
Analysis of the sequence of a known tumor suppressor
TP53 in a cohort of 491 diffuse large B-cell lymphoma
(DLBCL) patients revealed a widespread variation in the
TP53 3’UTR. A total of 187 novel single nucleotide vari-
ants (nSNV) and 6 known SNPs were identified. Inter-
estingly, impact of these nSNVs on survival depended on
the mutation status in the TP53 coding sequence (CDS):
in patients with the wild type TP53 CDS nSNVs con-
ferred better 5-year OS and PFS, while in patients with
mutated CDS nSNVs were associated with poorer OS
and PFS. Bioinformatics analysis showed that majority of
the nSNVs were located in validated or putative miRNA-
binding sites. Furthermore, it was shown in vitro that 3
nSNVs disrupting the binding site for miR-125b increase
p53 protein levels (Table 1). However, no correlation
was observed between the presence of nSNVs and ex-
pression of p53 in tumor samples, regardless of the mu-
tational status of the TP53 CDS. This could be due to
the fact that all nSNVs were analyzed collectively, while
some of them may have positive and some negative ef-
fect on the p53 expression [18]. This study highlights
the relevance of the interplay between miRSNPs and
mutations in the coding sequence of a gene. Since the
predicted effect of the majority of nSNVs was disruption
of miRNA-binding sites, elevated levels of wild type
tumor-suppressive p53 would be beneficial, while in-
creased expression of mutated, oncogenic p53 would be
unfavourable.
C14orf101/TMEM260 in non-Hodgkin lymphoma
Four polymorphisms chosen from a larger set of previ-
ously reported miRSNPs [9] were examined for associ-
ation with cancer risk and prognosis in non-Hodgkin
lymphoma. None of them was identified as a risk factor
Table 1 Polymorphisms in miRNA-binding sites in hematological malignancies
Gene SNP ID Variants Predicted to
affect binding
of










MM 137 OS p = 0.037 Effect on protein expression
confirmed in gene reporter








NHL 210 OS p = 0.012 Not examined [16]
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DLBCL 491 OS p = 0.019 Effect of three SNVs on miR-













NHL 210 233 Risk NS Not examined [16]
OS NS
NPM1 rs34351976 T > - miR-337-5p,
miR-887
AML 93 OS p = 0.016 Effect on miR-337-5p bind-
ing and protein expression
confirmed in gene reporter
assay, effect on mRNA
levels confirmed in vivo
[21]
RFS p = 0.007




101 471 Risk 1.9 (1.16-3.11),
p = 0.0107
Effect on miR-34c-5p and
miR-449b-5p binding and
protein expression confirmed
in gene reporter assay
[22]
TLX1 rs2742038 C > T miR-492 Childhood
ALL
101 471 Risk 3.97 (1.43-11.02),
p = 0.0081









101 471 Risk 0.55 (0.36-0.85),
p = 0.0079
Effect on miR-510-5p binding
and protein expression
confirmed in gene reporter
assay; no effect observed
for miR-589-3p
[22]
AML 87 471 Risk 0.6 (0.38-0.97),
p = 0.0372







IRF8 rs10514611 C > T miR-330-3p CML 140 471 Risk 2.4 (1.12-5.15),
p = 0.0246





ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CDS, coding sequence; CML, chronic myeloid leukemia; DFS, disease-free survival; DLBCL, diffuse
large B-cell lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NS, not significant; OR (95% CI), odds ratio (95% confidence
interval); OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival.
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tients and 90 controls) and should be replicated in a lar-
ger cohort. rs4901706 in C14orf101 was associated with
overall survival: the AA genotype was identified as an in-
dependent predictor of longer survival in a group of 359
NHL patients. Luciferase reporter assay in the HeLa cell
line showed that the G allele significantly reduced pro-
tein levels (Table 1) [19]. However, the study provided
no indication as to binding of which miRNA might be
affected nor the potential functional significance of al-
tered expression of C14orf101. Since nothing is known
about the functions of C14orf101, other than it encodes
for a transmembrane protein, it is hard to speculate how
altered levels of the protein may affect the prognosis of
NHL patients. Interestingly, a team from the same uni-
versity also studied rs4901706 in a group of 233 controls
and 210 NHL patients who were treated at the same
hospital and during the same period, and they did not
report any association of the SNP with NHL risk or
prognosis [16]. This discrepancy highlights the need for
studying the functional relevance of miRSNPs to corrob-
orate the findings from association studies.
NPM1 in acute myeloid leukemia
Significance of a polymorphic nucleotide T deletion
(rs34351976) in the 3’UTR of NPM1 was studied in acute
myeloid leukemia (AML). NPM1 encodes for nucleophos-
min, a molecular chaperone shuffling between nucleus
and cytoplasm. Mutations in NPM1 are found in about
one-third of adult AML patients but the exact mechanism
by which the mutant NPM1 protein contributes to
leukemogenesis remains unclear [20]. Although no differ-
ence in the frequency of delT polymorphism was observed
between AML patients and healthy controls, Cheng et al.
showed that overall and relapse-free survival was signifi-
cantly worse in patients carrying the homozygous delT.
Bioinformatics analysis combined with luciferase reporter
assay demonstrated that the delT polymorphism creates
an illegitimate binding site for miR-337-5p, which results
in decreased protein levels. This finding was confirmed in
patient samples: levels of NPM1 mRNA were significantly
lower in patients homozygous for the delT polymorphism
than in the non-homozygotes (Table 1). The mechanism
by which reduced levels of nucleophosmin resulting from
the homozygous delT polymorphism influence outcome
of AML patients remains to be elucidated [21].
5 miRSNPs in lymphoblastic and myeloid leukemias
Bioinformatics analysis of SNPs in the 3’UTRs of 137
leukemia-associated genes revealed 111 putative miRSNPs.
Based on the concordance of at least two algorithms used
in the analysis and the expression of predicted miRNAs in
blood cells or leukemias and lymphomas, the authors
selected 10 miRSNPs for genotyping in patients withchildhood acute lymphoblastic leukemia (ALL), adult
chronic (CML) and acute myeloid leukemia (AML), and
healthy controls. The study showed that homozygous
polymorphic genotypes of ETV6_rs1573613 and TLX1_
rs2742038 were associated with increased ALL risk, while
carriers of the variant allele of PML_rs9479 were at lower
risk of ALL and AML. Homozygous polymorphic geno-
types of ARHGAP26_rs187729 and IRF8_rs10514611 con-
ferred increased risk of CML. Furthermore, additive effect
of risk genotypes was demonstrated in ALL and CML. Risk
increased with each additional risk genotype carried by
a patient and surpassed the sum of individual ORs, reach-
ing 13.91 (4.38-44.11) for carriers of three or more risk
genotypes in ALL and 4.9 (1.27-18.85) for carriers of two
risk genotypes in CML. Effect of significant miRSNPs on
miRNA binding was evaluated by luciferase reporter assay
and confirmed for three miRSNPs: variant alleles of ARH-
GAP26_rs187729, ETV6_rs1573613 and PML_rs9479 were
shown to affect binding of miR-18a-3p, miR-34c-5p/miR-
449b-5p and miR-510-5p, respectively. TLX1_rs2742038
and IRF8_ rs10514611 were predicted to enhance binding
of miR-492 and miR-330-3p, respectively, but this was not
confirmed experimentally (Table 1) [22]. The study demon-
strated the relevance of polymorphisms in miRNA-binding
sites for various types of leukemia, however, the findings
should be validated in larger patient cohorts and the effect
of miRSNPs on the expression of genes and proteins should
be verified in vivo in patients samples. Also the mechanisms
by which the miRSNPs modulate leukemia risk still needs
to be elucidated, especially that the effect of miRSNPs in
ETV6 and PML on miRNA binding was not in line with
their role as tumor suppressors. This suggests that more
complicated miRNA regulatory networks might be affected,
according to the concept of ‘competing endogenous RNAs’
(ceRNA) [23].
Conclusions
More evidence is accumulating for the involvement of
deregulated miRNA networks in cancer development.
Polymorphisms in miRNA-binding sites of target genes
may disrupt miRNA-mediated regulation of gene expres-
sion by not only affecting the levels and function of the
given protein, but can also interfere with expression of
other genes targeted by the same miRNA.
So far only a few studies demonstrated the relevance of
miRNA target site polymorphisms for hematological ma-
lignancies, but this number will doubtless grow in the next
years. The studies presented in this review explored the
significance of miRSNPs for the risk or prognosis of blood
cancers to a different degree: some did not go beyond
reporting a significant association, while others pursued
the functional consequences of the miRSNPs. Based on
the work described in this review, it is evident that a com-
prehensive study of miRSNPs in disease should include
Dzikiewicz-Krawczyk Journal of Hematology & Oncology 2014, 7:83 Page 5 of 6
http://www.jhoonline.org/content/7/1/83several carefully planned and performed stages (Figure 1).
The first step is the selection of candidate miRSNPs.
Thorough scrutiny at this stage will increase the proba-
bility of finding miRSNPs of functional importance and fa-
cilitate interpretation of the results. Preferably, candidate
SNPs should be searched for in genes with proven rele-
vance for the disease in question, which will already give
hint for their functional significance. Several tools are
available for the prediction of the impact of SNPs on
miRNA binding, e.g. miRanda [24], PITA [25], SNPinfo
[26] and PolymiRTS [27], and since they use different algo-
rithms for miRNA target prediction, it is advisable to select
miRSNPs with the highest support from the available
tools. The set of thus selected miRSNPs should be further
narrowed down to those predicted to affect binding of
miRNAs that are expressed in the relevant cell type, using
databases integrating data on miRNA expression across
different tissues and cell types, such as mimiRNA [28] orSelect candidate miRSNPs
based on:
Gene relevance for the disease
Predicted effecton miRNA binding
miRNA expression in relevant cells
Determine allele and genotype frequency
in patient and control cohorts







of the miRSNP for the cell
Figure 1 A plan for a comprehensive study of miRNA-binding
site polymorphisms in disease.the non-coding RNA body map [29]. Allele and genotype
frequencies of the selected miRSNPs are then assessed in
appropriate patient and control groups to identify miRSNPs
associated with disease risk or prognosis. For statistically
significant miRSNPs their impact on binding of miRNAs
predicted by the in silico analysis should be verified, ideally
both in vitro and in vivo. Gene reporter assays (e.g. lucifer-
ase assay) allow to identify specific miRNAs which bind dif-
ferentially to the wild-type and variant 3’UTRs. Depending
on whether or not the miRNA of interest is expressed in
the cell line used in luciferase assay, miRNA mimics and/or
inhibitors need to be used in the assay to ensure that the
observed effect can be attributed to the specific miRNA.
mRNA and protein expression should be also compared
between different genotypes in vivo in relevant samples,
taking into account levels of specific miRNAs in individual
samples. Finally, based on the known functions of the pro-
tein encoded by the gene bearing the miRSNP, appropriate
tests should be performed to unravel functional conse-
quences of the miRSNP, which could explain their impact
on the disease risk or prognosis. In case no significant ef-
fects are observed, an alternative possibility worth consider-
ing is an indirect impact of a miRSNP on expression of
other genes targeted by the same miRNA through changes
in the pool of miRNA available for binding in the cell. It
has been proposed that different classes of RNA transcripts
– mRNAs, pseudogenes and long non-coding RNAs –
compete for miRNA binding, intertwined in a large regula-
tory network. The “competing endogenous RNA” (ceRNA)
hypothesis assumes that RNAs communicate with each
other through miRNAs and miRNA recognition sequences
[23]. Thus, the effect of a miRSNP may extend beyond ex-
pression of the gene bearing the polymorphism, and influ-
ence other RNAs regulated by the same miRNA.
In conclusion, polymorphisms in miRNA-binding sites
not only offer a possibility of novel diagnostic and prog-
nostic markers in hematological malignancies, but can
also help to understand complex regulatory networks of
miRNAs in health and disease. With the development of
more sophisticated bioinformatics algorithms and accu-
mulation of data from sequencing of cancer genomes,
identification of miRSNPs of clinical utility and func-
tional relevance for hematological malignancies should
be facilitated.
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